Work

HIV PrEP Dose Rationale for Cabotegravir (GSK1265744) Long-acting Injectable Nanosuspension

Year: 2014

Type: conference-abstract

Source: AIDS Research and Human Retroviruses

DOI: 10.1089/aid.2014.5010a.abstract

Authors: Bill Spreen, Alex Rinehart, Kimberly Smith, David Margolis, Susan Ford, Steve Piscitelli

Institution: GlaxoSmithKline (United States)

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2312737305

Cites:

Cited by: 4

Related to: 10